The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials

Follicular lymphoma (FL) patients treated with firstline R‐CHOP who experience progression of disease (POD) within 2 years have a shorter survival than those who do not have POD within 2 years. Whether this observation holds for patients treated initially with biologic immunotherapy alone is unknown...

Descripción completa

Detalles Bibliográficos
Autores principales: Lansigan, Frederick, Barak, Ian, Pitcher, Brandelyn, Jung, Sin‐Ho, Cheson, Bruce D., Czuczman, Myron, Martin, Peter, Hsi, Eric, Schöder, Heiko, Smith, Scott, Bartlett, Nancy L., Leonard, John P., Blum, Kristie A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346218/
https://www.ncbi.nlm.nih.gov/pubmed/30575311
http://dx.doi.org/10.1002/cam4.1918

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346218/
https://www.ncbi.nlm.nih.gov/pubmed/30575311
http://dx.doi.org/10.1002/cam4.1918

Ejemplares similares